Page 193 - EJMO-9-3

Eurasian Journal of Medicine

and Oncology

ORIGINAL RESEARCH ARTICLE
Basic medication therapy based on target

glycated hemoglobin levels in patients with
ischemic heart disease and diabetes

Raisa Trigulova 1† , Alisher Ikramov 2,3† * , Dilnoza Alimova 1 ,
Shukhrat Doniyorov 1 , Dilafruz Akhmedova 1 , and Shakhnoza Mukhtarova 4
1 Scientific Laboratory of Preventive Cardiology, The Republican Specialized Scientific-Practical
Medical Center of Cardiology, Tashkent, Uzbekistan
2 Department of Mathematics, School of Humanities, Natural, and Social Sciences, New Uzbekistan
University, Tashkent, Uzbekistan
3 Laboratory of Biomedical Informatics, V.I. Romanovskiy Institute of Mathematics, Uzbekistan
Academy of Sciences, Tashkent, Uzbekistan
4 Department of Pediatric Endocrinology, Medical-Pedagogical and Medical Faculty, Tashkent
Pediatric Medical Institute, Tashkent, Uzbekistan

Abstract
Introduction: Type 2 diabetes mellitus (T2DM) and ischemic heart disease (IHD)
are significant medical conditions. Research indicates that patients with T2DM have
a substantially increased risk of developing cardiovascular diseases, necessitating
† These authors contributed equally
to this work. meticulous monitoring and management of both diabetes and associated
cardiovascular conditions. Achieving target glycated hemoglobin (HbA1c) levels is
*Corresponding author:
Alisher Ikramov crucial for effective T2DM treatment.
(a.ikramov@newuu.uz) Objective: This study investigates the prescribed basic medication therapy in patients
with T2DM and IHD based on target HbA1c levels.
Citation: Trigulova R, Ikramov A,
Alimova D, Doniyorov S, Methods: A prospective observational study was conducted at the Republican
Akhmedova D, Mukhtarova S. Specialized Scientific-Practical Medical Center of Cardiology in Uzbekistan from 2022 to
Basic medication therapy based on 2024, involving 130 patients with T2DM and IHD. Clinical, functional, and instrumental
target glycated hemoglobin levels in
patients with ischemic heart disease parameters, including left ventricular ejection fraction and other metabolic indicators,
and diabetes. Eurasian J Med were assessed. Data were collected using standardized questionnaires and analyzed
Oncol. 2025;9(3):185-196. using the Statistical Package for Social Sciences. Logistic and linear regression models
doi: 10.36922/EJMO025160133
were used to analyze the efficiency of medication treatment.
Received: April 18, 2025 Results: Among the cohort, 56.9% achieved an HbA1c level ≤8%, while 43.1% had an HbA1c
Revised: May 8, 2025 level ≥8%. Significant differences were observed in age, gender distribution, duration of
diabetes, and IHD between the two groups. Medication therapy varied significantly, with
Accepted: June 4, 2025
higher usage of metformin and insulin in patients with an HbA1c level ≥8%. The linear
Published online: July 28, 2025 regression model predicts HbA1c levels based on clinical data and dosages of prescribed
Copyright: © 2025 Author(s). medications with a root mean square error of 1.172 and a Spearman correlation coefficient
This is an Open-Access article of 0.826. The logistic regression model predicts achievement of target HbA1c levels with a
distributed under the terms of the
Creative Commons Attribution receiver operating characteristic area under the curve value of 0.92.
License, permitting distribution, Conclusion: The study highlights the importance of individualized medication
and reproduction in any medium, therapy tailored to HbA1c levels to improve clinical outcomes in patients with T2DM
provided the original work is
properly cited. and IHD. It also highlights differences in medication effects based on the target
HbA1c levels in patients.
Publisher’s Note: AccScience
Publishing remains neutral with Keywords: Diabetes mellitus; Ischemic heart disease; Glycated hemoglobin; Medication
regard to jurisdictional claims in
published maps and institutional therapy
affiliations.

Volume 9 Issue 3 (2025) 185 doi: 10.36922/EJMO025160133